Health news
Janssen announced that it has filed a lawsuit in the United States District Court for the Eastern District of New York seeking seizure of counterfeit HIV medications from unauthorized distributors. The legal action follows an…
Point-of-care (POC) HIV RNA viral load testing was found to accurately diagnose antiretroviral therapy (ART) treatment failure (HIV RNA viral load, ≥1000 copies/mL) in patients with HIV infection, according to findings published in Cochrane Database…
The Food and Drug Administration (FDA) has expanded the approval of Cabenuva (cabotegravir and rilpivirine) injection to include the treatment of HIV-1 in virologically suppressed adolescents (HIV-1 RNA less than 50 copies/mL) who are 12…
Treatment for substance use disorders (SUD) and infectious disease (ID) has traditionally been viewed as the individual responsibility of mental health professionals and ID physicians, respectively. However, the need for an integrated treatment approach has…
In 2018, approximately half (43%) of all new diagnoses of HIV infection in the United States were among the Black population, indicating the need for effective strategies to decrease the risk for HIV transmission in…
The Food and Drug Administration (FDA) has approved Cabenuva (cabotegravir and rilpivirine) injection for every 2-month dosing for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are…
Gilead Sciences has announced the removal of counterfeit and tampered Gilead-labeled HIV medications, including bottles labeled as Biktarvy® (bictegravir, emtricitabine, tenofovir alafenamide) and Descovy® (emtricitabine and tenofovir alafenamide), from the US supply chain. Biktarvy is…
A multicomponent diagnostic strategy was found to increase the number of patients being tested, diagnosed, and treated for confirmed tuberculosis (TB) infection, according to results of a cluster-randomized study published in The New England Journal…
The Food and Drug Administration (FDA) has approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35kg for preexposure prophylaxis (PrEP) to reduce the risk of sexually acquired…
The Food and Drug Administration (FDA) has placed clinical holds on studies evaluating islatravir (MK-8591), an investigational nucleoside reverse transcription translocation inhibitor, for the treatment and prevention of HIV-1 infection. The clinical holds were based…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021